Paraneoplastic cerebellar degeneration and dermatomyositis as first manifestations of underlying breast malignancy: a report of two cases and a brief review of the subject by Ying Ru Yvonne Ng et al.
Ng et al. Surgical Case Reports  (2015) 1:59 
DOI 10.1186/s40792-015-0063-zCASE REPORT Open AccessParaneoplastic cerebellar degeneration and
dermatomyositis as first manifestations of
underlying breast malignancy: a report of
two cases and a brief review of the subject
Ying Ru Yvonne Ng1*, Chunyin Derek Ho1, Weng Leong Victor Ng2 and Su-Ming Tan1Abstract
Paraneoplastic syndromes are rare first manifestations of breast cancer. In this report, we present two cases of a
58-year-old woman and a 69-year-old woman presenting with acute symptoms of paraneoplastic cerebellar degeneration
(PCD) and dermatomyositis, respectively, as the first sign of breast malignancy. The patient diagnosed with PCD presented
initially with ataxia, was serum anti-Yo antibody negative, and subsequently investigated to have poorly differentiated
intraductal breast carcinoma. Cerebellar symptoms regressed following breast cancer surgery and chemotherapy,
highlighting the better neurological prognosis associated with anti-Yo antibody negative PCD. The rarity of these
presentations highlights the necessity to include an occult malignancy in the differential diagnosis when attending to
such patients.
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Paraneoplastic syndromes are hypothesized to be trig-
gered by an abnormal autoimmune system response to
an underlying malignancy or by humoral factors
expressed by tumour cells [1]. While breast malignancy
commonly presents as a breast lump or a suspicious
radiological finding, 1–3 % have non-metastatic-related
paraneoplastic manifestations [2]. Several studies have
documented the association between breast cancer and
dermatomyositis [3], whereas the association between
paraneoplastic cerebellar degeneration (PCD) and breast
malignancy is less known with only a handful of cases
reported. However, few of such cases have been cited in
Asia, and to our knowledge, this is the first report for
both paraneoplastic presentations in Southeast Asia. We
present two women who first showed cerebellar signs
and skin rash that were subsequently attributed to
underlying breast cancer.* Correspondence: yvonne.ng@mohh.com.sg
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Case presentation 1
A 58-year-old woman with no past medical history or
intake of chronic medications experienced progressively
worsening vertiginous giddiness and unsteadiness for
1 week, associated with noticeably impaired coordin-
ation and speech slurring for 2 days. Neurological
examination found gaze-evoked rotatory nystagmus,
diplopia, bilateral dysmetria and dysdiadochokinesia,
dysarthria and gait ataxia. To diagnose the cerebellar
disorder, biochemical, cerebrospinal fluid and radio-
logical tests were performed to rule out infective
causes, metabolic causes including hypothyroidism and
vitamin B12 deficiency, autoimmune causes including
celiac disease and glutamate decarboxylase autoanti-
bodies, neurodegenerative disease including Miller
Fisher syndrome, and primary or metastatic cerebellar
lesion. The only significant biochemical result was a
positive antinuclear antibody level. Magnetic resonance
imaging (MRI) of the brain for a stroke or cerebellar
disorder was negative. Suspicion of paraneoplastic cere-
bellar presentation was raised, and she was evaluated
for a primary lesion. Cerebrospinal fluid (CSF) analysisdistributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Fig. 2 Erythematous rash typical of dermatomyositis on the patient’s
neck and shoulders in a classical shawl distribution. Skin punch
biopsy site on the left chest wall
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bands indicative of intrathecal immunoglobulin (Ig) G
synthesis. CSF and serum anti-neuronal antibodies
(anti-Yo) were however negative. High-dose intraven-
ous Ig was commenced with no improvement. Com-
puted tomography (CT) scan of the chest, abdomen
and pelvis detected a right breast ten o’clock enhancing
nodule with irregular margins associated with enlarged
axillary and subpectoral nodes (Fig. 1). Breast imaging
confirmed multicentric breast lesions with axillary
adenopathy compatible with malignancy and nodal
metastasis. Breast biopsy established a grade 3 invasive
ductal carcinoma (IDC) with oestrogen, progesterone
and HER-2 receptor statuses negative.
Pathological staging returned as T1BN1M0 (stage IIa)
after modified radical mastectomy (MRM). The patient
underwent adjuvant chemotherapy and rehabilitation
for her neurological condition. She regained func-
tional independence with resolution of her physical
impairment 3 months post-operation and remained
disease-free since.
Case presentation 2
A 69-year-old woman experienced 3 months of atypical
chest pain, erythematous rash over her face and sun-
exposed areas in a classical shawl distribution (Fig. 2),
arthralgia, and proximal upper extremity muscle fatigue
and weakness in a symmetrical distribution. She was ad-
mitted into cardiology by the emergency department.
However, clinical impression of inpatient dermatology
and rheumatology consults was dermatomyositis (DM).
Creatine kinase 1409 U/L and aldolase 7.6 U/L were ele-
vated, but anti-nuclear antibodies were negative. Electro-
myography showed myopathic changes, muscle biopsy
displayed diffuse expression of MHC class I antigen on
immunostaining supportive of underlying inflammatoryFig. 1 Computed tomography of the chest showing the right breast
nodule with irregular marginsmyopathy, and skin punch biopsy was consistent with
DM (Fig. 3).
Examination for an occult malignancy found a right
enlarged axillary lymph node. Breast imaging found
two irregular marginated nodules in the inner right
breast with malignant features. Breast biopsy confirmed
grade 3 IDC with negative oestrogen and progesterone
receptor status but positive HER-2 receptor status. The
cancer was staged as IIIc T2N3M0 after right MRM with
a tumour size of 45 mm and 20 positive lymph nodes.
Adjuvant chemotherapy, radiotherapy, Herceptin and
oral prednisolone were administered. The dermal lesions,
arthralgia and myasthenia completely regressed within
4 months post-operation, and the patient remained
disease-free for 21 months. The DM rash, however,
reappeared 21 months post operation, and a computed
tomography scan performed confirmed disease relapse
with radiological findings characteristic of hepatic and
pulmonary metastasis.
Discussion
The etiological relationship between cerebellar degener-
ation and malignancy was first detailed by Brain et al. in
1951 [4]. Graus et al. in 2004 designed a diagnostic
criterion of a neurological syndrome as paraneoplastic
based on the (1) presence or absence of cancer,
the (2) definitions of classical syndrome and (3) well-
characterized onconeural antibody [5]. PCD is mediated
by onconeural antibodies (ONAs) produced against
tumour antigens. Anti-Yo antibody is the most com-
mon ONA associated with PCD followed by anti-Hu,
anti-Tr and anti-Ri [6, 7]. Cdr2, also known as Purkinje
neuronal protein, is expressed on cells within the cere-
bellum and is similar to the tumour antigen that is
expressed in breast and ovarian tumours for anti-Yo
antibody [8]. Cross-reaction between the ONAs and
Fig. 3 a Haematoxylin-eosin stain of skin biopsy showing perivascular and interface lymphocytes and dermis edema and mucin that are
characteristic of dermatomyositis. (×100 magnification). b Alcian Blue stain of skin of the skin biopsy highlighting the increased dermal
mucin in the superficial dermis that is characteristic of dermatomyositis. (×40 magnification)
Table 1 Bohan and Peter’s criteria for diagnosis of
dermatomyositis
Individual criteria
1. Symmetric proximal muscle weakness
2. Muscle biopsy evidence of myositis
3. Increase in serum skeletal muscle enzymes
4. Characteristic electromyogram pattern of myositis
5. Typical rash of dermatomyositis
Diagnostic criteria
• Definite: 5 plus any three of 1 to 4
• Probable: 5 plus any two of 1 to 4
• Possible: 5 plus any one of 1 to 4
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mediated responses that cause cerebellar injury and
neuronal dysfunction. Animal models suggest that cdr2
downregulate c-Myc proto-oncogenes in the neuronal
cytoplasm. ONAs have been demonstrated to disrupt
cdr2-c-Myc interactions, potentially leading to in-
creased c-Myc activity and eventual apoptosis of the
Purkinje cells [9]. Recent literature suggests that while
ONAs play an initial pathogenic role in PCD, and cyto-
toxic T-lymphocytes also contribute to the neuronal
degeneration [10]. Cerebellar cognitive affective syn-
drome, in which slight memory and cognitive deficits and
affective symptoms are displayed, may occur in 20 % [8].
Thorough investigation including CSF examination and
serum tumour markers should be performed in a patient
with PCD. CSF may have raised protein and IgG, predom-
inant lymphocytic pleocytosis and positive oligoclonal
banding as in our patient [11]. With disease progres-
sion, MRI brain scan may show generalized cerebellar
atrophy [12, 13].
Treatment is aimed at the eradication of the malig-
nancy with supportive rehabilitation of the cerebellar
abnormality. No randomized control trials exist to
establish a treatment protocol but attempts to treat the
neurological dysfunction with chemotherapy, immuno-
globulins, plasmapheresis and/or immunosuppression
have yielded poor response [14]. While tumour progno-
sis and survival in negative anti-Yo antibody PCD
patients is similar to those with normal breast cancer,
anti-Yo antibody positive patients are reported to have
a more aggressive cerebellar disease course with more
than 90 % eventually requiring an assistive device for
ambulation and significantly poorer overall survival
(median 100 months) [11, 14]. Our patient highlights
the better prognosis in negative anti-Yo antibody PCD.
DM is an autoimmune inflammatory myopathy with
characteristic cutaneous findings that include pathogno-
monic heliotrope rash, Gottron’s papules or a rash
eruption in a photosensitive distribution [15]. Proximal
muscle fatigue or weakness may occur. In 1975, Bohanand Peter presented the criteria to aid diagnosis, and
our patient met the definite criteria (Table 1) [16]. The
association between DM and malignancy is well-
established and reported in 15–30 % of adult-onset DM
with increased frequency with age. Ovarian and lung
tumours are the most commonly linked in female and
males, respectively. Paraneoplastic DM is not associated
with poorer prognosis and commonly demonstrates a
parallel regression of the dermal lesions and muscular
symptoms when the cancer is in remission and return
with malignancy recurrence as highlighted by our pa-
tient. Hence, clinical follow up for these patients should
include observation of recurrent cutaneous signs or
myopathy. However, breast carcinoma may sometimes
be associated with amyopathic DM which is character-
ized by the absence of myopathy. It is suggested that
amyopathic DM is not responsive either to steroid
treatment and does not regress despite eradication of
malignancy.
Conclusions
In conclusion, while tumour prognosis per se is similar
to patients who present in the normal manner, early
tumour eradication slows the autoimmune response,
allowing a chance for paraneoplastic symptom remission
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maintain a high level of clinical vigilance for paraneoplas-
tia and assessment for malignancy upon initial diagnosis
to prevent delayed management and irreversible damage,
neurological or otherwise.
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